1,470
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Common Risk Allele in Aromatic Antiepileptic-Drug Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Han Chinese

, , , , , , & show all
Pages 349-356 | Published online: 17 Mar 2010

Bibliography

  • Toledano R , Gil-NagelA: Adverse effects of antiepileptic drugs.Semin. Neurol.28(3) , 317–327 (2008).
  • Kennedy GM , LhatooSD: CNS adverse events associated with antiepileptic drugs.CNS Drugs22(9) , 739–760 (2008).
  • Arif H , BuchsbaumR, WeintraubD et al.: Comparison and predictors of rash associated with 15 antiepileptic drugs.Neurology68(20) , 1701–1709 (2007).
  • Krivoy N , TaerM, NeumanMG: Antiepileptic drug-induced hypersensitivity syndrome reactions.Curr. Drug. Saf.1(3) , 289–299 (2006).
  • Roujeau JC : The spectrum of Stevens–Johnson syndrome and toxic epidermal necrolysis: a clinical classification.J. Invest. Dermatol.102(6) , S28–S30 (1994).
  • Mockenhaupt M , MessenheimerJ, TennisP, SchlingmannJ: Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.Neurology64(7) , 1134–1138 (2005).
  • Mockenhaupt M , ViboudC, DunantA et al.: The EuroSCAR-study. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs.J. Invest. Dermatol.128(1) , 35–44 (2008).
  • Nassif A , BensussanA, BoumsellL et al.: Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.J. Allergy. Clin. Immunol.114(5) , 1209–1215 (2004).
  • Chung WH , HungSI, YangJY et al.: Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis.Nat. Med.14(12) , 1343–1350 (2008).
  • Chung WH , HungSI, HongHS et al.: Medical genetics: a marker for Stevens–Johnson syndrome.Nature428(6982) , 486 (2004).
  • Hung SI , ChungWH, JeeSH et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.Pharmacogenet. Genomics16(4) , 297–306 (2006).
  • Hung SI , ChungWH, ChenYT: HLA-B genotyping to detect carbamazepine-induced Stevens–Johnson syndrome: implications for personalizing medicine.Personalized Medicine2(3) , 225–237 (2005).
  • Lonjou C , ThomasL, BorotN et al.: RegiSCAR Group. A marker for Stevens–Johnson syndrome…: ethnicity matters.Pharmacogenomics J.6(4) , 265–268 (2006).
  • Man CB , KwanP, BaumL et al.: Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.Epilepsia48(5) , 1015–1018 (2007).
  • Locharernkul C , LoplumlertJ, LimotaiC et al.: Carbamazepine and phenytoin induced Stevens–Johnson syndrome is associated with HLA-B*1502 allele in Thai population.Epilepsia49(12) , 2087–2091 (2008).
  • Knowles SR , ShapiroLE, ShearNH: Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.Drug Saf.21(6) , 489–501 (1999).
  • Hirsch LJ , ArifH, NahmEA, BuchsbaumR, ResorSR Jr, Bazil CW: Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology71(19) , 1527–1534 (2008).
  • Alvestad S , LydersenS, BrodtkorbE: Cross-reactivity pattern of rash from current aromatic antiepileptic drugs.Epilepsy Res.80(2–3) , 194–200 (2008).
  • Seitz CS , PfeufferP, RaithP, BröckerEB, TrautmannA: Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents.Ann. Allergy Asthma Immunol.97(5) , 698–702 (2006).
  • Chen YC , ChuCY, HsiaoCH: Oxcarbazepine-induced Stevens–Johnson syndrome in a patient with HLA-B*1502 genotype.J. Eur. Acad. Dermatol. Venereol.23(6) , 702–703 (2009).
  • Pan WH , FannCS, WuJY et al.: Han Chinese cell and genome bank in Taiwan: purpose, design and ethical considerations.Hum. Hered.61(1) , 27–30 (2006).
  • Middleton D : Current and emerging technology for HLA typing.Int. J. Hematol.76(Suppl. 2) , 150–151 (2002).
  • Tilanus MGJ , HansenJA, HurleyCK: IHWG Technical Manual Genomic Analysis of the Human MHC, DNA-Based Typing for HLA Alleles and Linked Polymorphisms 2000. Publication of the 13th International Histocompatibility Working Group. Tilanus MGJ, Hansen JH, Hurley CK (Eds). Fred Hutchinson Cancer Research Center, WA, USA, ISBN number: 0-945278-02-0 (2002).
  • Hung SI , ChungWH, LiouLB et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Proc. Natl. Acad. Sci. USA102(11) , 4134–4139 (2005).
  • Chu CC , LinM, NakajimaF et al.: Diversity of HLA among Taiwan‘s indigenous tribes and the Ivatans in the Philippines.Tissue Antigens58(1) , 9–18 (2001).
  • Haldane JB : The estimation and significance of the logarithm of a ratio of frequencies.Ann. Hum. Genet.20(4) , 309–311 (1956).
  • Lonjou C , BorotN, SekulaPS et al.; RegiSCAR Study Group: A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics18(2) , 99–107 (2008).
  • Kazeem GR , CoxC, AponteJ et al.: High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients.Pharmacogenet Genomics.19(9) , 661–665 (2009).
  • Kaniwa N , SaitoY, AiharaM et al.; JSAR Research Group: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics9(11) , 1617–1622 (2008).
  • Alfirevic A , JorgensenAL, WilliamsonPR, ChadwickDW, ParkBK, PirmohamedM: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity.Pharmacogenomics7(6) , 813–818 (2006).
  • Kano Y , HiraharaK, AsanoY, ShioharaT: HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions.Acta Derm. Venereol.88(6) , 616–618 (2008).
  • Kashiwagi M , AiharaM, TakahashiY et al.: Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients.J. Dermatol.35(10) , 683–685 (2008).
  • Lin LC , LaiPC, YangSF, YangRC: Oxcarbazepine-induced Stevens–Johnson syndrome: a case report.Kaohsiung J. Med. Sci.25(2) , 82–86 (2009).
  • LaRoche S , HelmersSL: The new antiepileptic drugs.JAMA291(5) , 605–614 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.